WO2018002173A1 - Method of detecting copd by mass spectrometry - Google Patents
Method of detecting copd by mass spectrometry Download PDFInfo
- Publication number
- WO2018002173A1 WO2018002173A1 PCT/EP2017/066053 EP2017066053W WO2018002173A1 WO 2018002173 A1 WO2018002173 A1 WO 2018002173A1 EP 2017066053 W EP2017066053 W EP 2017066053W WO 2018002173 A1 WO2018002173 A1 WO 2018002173A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- metabolites
- acid
- computer
- sample
- copd
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 67
- 238000004949 mass spectrometry Methods 0.000 title claims description 6
- 239000002207 metabolite Substances 0.000 claims abstract description 127
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims abstract description 28
- 150000001413 amino acids Chemical class 0.000 claims abstract description 23
- 230000008569 process Effects 0.000 claims abstract description 18
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims abstract description 16
- 230000001590 oxidative effect Effects 0.000 claims abstract description 16
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims abstract description 14
- 239000002253 acid Substances 0.000 claims description 31
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 27
- 229930195729 fatty acid Natural products 0.000 claims description 27
- 239000000194 fatty acid Substances 0.000 claims description 27
- 150000004665 fatty acids Chemical class 0.000 claims description 24
- 235000001014 amino acid Nutrition 0.000 claims description 22
- 229940024606 amino acid Drugs 0.000 claims description 22
- 150000007513 acids Chemical class 0.000 claims description 21
- 238000004458 analytical method Methods 0.000 claims description 21
- 238000007254 oxidation reaction Methods 0.000 claims description 19
- 238000003745 diagnosis Methods 0.000 claims description 18
- 230000035882 stress Effects 0.000 claims description 15
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims description 12
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 claims description 12
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 claims description 12
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims description 12
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 229940116269 uric acid Drugs 0.000 claims description 12
- IQUPABOKLQSFBK-UHFFFAOYSA-N 2-nitrophenol Chemical class OC1=CC=CC=C1[N+]([O-])=O IQUPABOKLQSFBK-UHFFFAOYSA-N 0.000 claims description 11
- 230000008599 nitrosative stress Effects 0.000 claims description 11
- 210000002345 respiratory system Anatomy 0.000 claims description 11
- 150000002500 ions Chemical class 0.000 claims description 8
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 6
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 6
- 235000003704 aspartic acid Nutrition 0.000 claims description 6
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 6
- VIIYYMZOGKODQG-UHFFFAOYSA-N 2-nitrobenzene-1,4-diol Chemical class OC1=CC=C(O)C([N+]([O-])=O)=C1 VIIYYMZOGKODQG-UHFFFAOYSA-N 0.000 claims description 5
- 238000012545 processing Methods 0.000 claims description 5
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 claims description 4
- 150000004668 long chain fatty acids Chemical class 0.000 claims description 4
- 150000004667 medium chain fatty acids Chemical class 0.000 claims description 4
- 229920006395 saturated elastomer Chemical class 0.000 claims description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 3
- MHKBMNACOMRIAW-UHFFFAOYSA-N 2,3-dinitrophenol Chemical class OC1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O MHKBMNACOMRIAW-UHFFFAOYSA-N 0.000 claims description 3
- BWLBGMIXKSTLSX-UHFFFAOYSA-N 2-hydroxyisobutyric acid Chemical compound CC(C)(O)C(O)=O BWLBGMIXKSTLSX-UHFFFAOYSA-N 0.000 claims description 3
- QPDMNFFZLIUVIV-UHFFFAOYSA-N 2-oxo-heptadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)C(O)=O QPDMNFFZLIUVIV-UHFFFAOYSA-N 0.000 claims description 3
- YHKWFDPEASWKFQ-UHFFFAOYSA-N 3-nitrobenzene-1,2-diol Chemical class OC1=CC=CC([N+]([O-])=O)=C1O YHKWFDPEASWKFQ-UHFFFAOYSA-N 0.000 claims description 3
- UQBOJOOOTLPNST-UHFFFAOYSA-N Dehydroalanine Chemical compound NC(=C)C(O)=O UQBOJOOOTLPNST-UHFFFAOYSA-N 0.000 claims description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 3
- 239000004471 Glycine Substances 0.000 claims description 3
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 3
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims description 3
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 3
- 239000004472 Lysine Substances 0.000 claims description 3
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims description 3
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims description 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 3
- 235000004279 alanine Nutrition 0.000 claims description 3
- 235000018417 cysteine Nutrition 0.000 claims description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 3
- 235000013922 glutamic acid Nutrition 0.000 claims description 3
- 239000004220 glutamic acid Substances 0.000 claims description 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 3
- 229960000310 isoleucine Drugs 0.000 claims description 3
- 229960003104 ornithine Drugs 0.000 claims description 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 3
- 235000004400 serine Nutrition 0.000 claims description 3
- 239000004474 valine Substances 0.000 claims description 3
- 150000004669 very long chain fatty acids Chemical class 0.000 claims description 3
- UHZWUNLTEZCDMA-UHFFFAOYSA-N (10r)-10-hydroxyundecanoic acid Chemical compound CC(O)CCCCCCCCC(O)=O UHZWUNLTEZCDMA-UHFFFAOYSA-N 0.000 claims description 2
- SZQQHKQCCBDXCG-BAHYSTIISA-N (2e,4e,6e)-hexadeca-2,4,6-trienoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C(O)=O SZQQHKQCCBDXCG-BAHYSTIISA-N 0.000 claims description 2
- QSADEFUCCLBNRO-UHFFFAOYSA-N 4-oxotetradec-2-enoic acid Chemical compound O=C(C=CC(=O)O)CCCCCCCCCC QSADEFUCCLBNRO-UHFFFAOYSA-N 0.000 claims description 2
- 238000000132 electrospray ionisation Methods 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 description 14
- 239000000090 biomarker Substances 0.000 description 9
- 238000013125 spirometry Methods 0.000 description 6
- 239000004810 polytetrafluoroethylene Substances 0.000 description 5
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- YJCJVMMDTBEITC-UHFFFAOYSA-N 10-hydroxycapric acid Chemical compound OCCCCCCCCCC(O)=O YJCJVMMDTBEITC-UHFFFAOYSA-N 0.000 description 4
- ZDHCZVWCTKTBRY-UHFFFAOYSA-N 12-hydroxylauric acid Chemical compound OCCCCCCCCCCCC(O)=O ZDHCZVWCTKTBRY-UHFFFAOYSA-N 0.000 description 4
- DWXOPJCPYKBNEC-UHFFFAOYSA-N 13-hydroxytridecanoic acid Chemical compound OCCCCCCCCCCCCC(O)=O DWXOPJCPYKBNEC-UHFFFAOYSA-N 0.000 description 4
- JOSXCARTDOQGLV-UHFFFAOYSA-N 14-hydroxymyristic acid Chemical compound OCCCCCCCCCCCCCC(O)=O JOSXCARTDOQGLV-UHFFFAOYSA-N 0.000 description 4
- BZUNJUAMQZRJIP-UHFFFAOYSA-N 15-hydroxypentadecanoic acid Chemical compound OCCCCCCCCCCCCCCC(O)=O BZUNJUAMQZRJIP-UHFFFAOYSA-N 0.000 description 4
- KDMSVYIHKLZKET-UHFFFAOYSA-N 8-hydroxyoctanoic acid Chemical compound OCCCCCCCC(O)=O KDMSVYIHKLZKET-UHFFFAOYSA-N 0.000 description 4
- BTZVDPWKGXMQFW-UHFFFAOYSA-N Pentadecanedioic acid Chemical compound OC(=O)CCCCCCCCCCCCCC(O)=O BTZVDPWKGXMQFW-UHFFFAOYSA-N 0.000 description 4
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 4
- JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 4
- WLJVNTCWHIRURA-UHFFFAOYSA-N pimelic acid Chemical compound OC(=O)CCCCCC(O)=O WLJVNTCWHIRURA-UHFFFAOYSA-N 0.000 description 4
- 230000029058 respiratory gaseous exchange Effects 0.000 description 4
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical compound OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 description 4
- TYFQFVWCELRYAO-UHFFFAOYSA-N suberic acid Chemical compound OC(=O)CCCCCCC(O)=O TYFQFVWCELRYAO-UHFFFAOYSA-N 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- HQHCYKULIHKCEB-UHFFFAOYSA-N tetradecanedioic acid Chemical compound OC(=O)CCCCCCCCCCCCC(O)=O HQHCYKULIHKCEB-UHFFFAOYSA-N 0.000 description 4
- LWBHHRRTOZQPDM-UHFFFAOYSA-N undecanedioic acid Chemical compound OC(=O)CCCCCCCCCC(O)=O LWBHHRRTOZQPDM-UHFFFAOYSA-N 0.000 description 4
- 239000012855 volatile organic compound Substances 0.000 description 4
- QFGCFKJIPBRJGM-UHFFFAOYSA-N 12-[(2-methylpropan-2-yl)oxy]-12-oxododecanoic acid Chemical compound CC(C)(C)OC(=O)CCCCCCCCCCC(O)=O QFGCFKJIPBRJGM-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- -1 aliphatic fatty acids Chemical class 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 238000001819 mass spectrum Methods 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000000241 respiratory effect Effects 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- KNRCBASNXNXUQQ-UHFFFAOYSA-N 11-hydroxyundecanoic acid Chemical compound OCCCCCCCCCCC(O)=O KNRCBASNXNXUQQ-UHFFFAOYSA-N 0.000 description 2
- ZGPVCRPNBPLGDV-UHFFFAOYSA-N 11-oxoundecanoic acid Chemical compound OC(=O)CCCCCCCCCC=O ZGPVCRPNBPLGDV-UHFFFAOYSA-N 0.000 description 2
- KGEACANGAYABKT-UHFFFAOYSA-N 12-oxododecanoic acid Chemical compound OC(=O)CCCCCCCCCCC=O KGEACANGAYABKT-UHFFFAOYSA-N 0.000 description 2
- DRJBSGNVRUEBDG-UHFFFAOYSA-N 13-oxotridecanoic acid Chemical compound OC(=O)CCCCCCCCCCCC=O DRJBSGNVRUEBDG-UHFFFAOYSA-N 0.000 description 2
- VRNVZSGJXRCUTI-UHFFFAOYSA-N 14-oxotetradecanoic acid Chemical compound OC(=O)CCCCCCCCCCCCC=O VRNVZSGJXRCUTI-UHFFFAOYSA-N 0.000 description 2
- YIIGIORMMKPIOL-UHFFFAOYSA-N 15-oxopentadecanoic acid Chemical compound OC(=O)CCCCCCCCCCCCCC=O YIIGIORMMKPIOL-UHFFFAOYSA-N 0.000 description 2
- UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 description 2
- UWEZBKLLMKVIPI-UHFFFAOYSA-N 2,5-dinitrophenol Chemical compound OC1=CC([N+]([O-])=O)=CC=C1[N+]([O-])=O UWEZBKLLMKVIPI-UHFFFAOYSA-N 0.000 description 2
- KBPCCVWUMVGXGF-UHFFFAOYSA-N 2,6-dimethylheptane Chemical compound CC(C)CCCC(C)C KBPCCVWUMVGXGF-UHFFFAOYSA-N 0.000 description 2
- HOSWPDPVFBCLSY-UHFFFAOYSA-N 2-azaniumyl-4-oxobutanoate Chemical compound OC(=O)C(N)CC=O HOSWPDPVFBCLSY-UHFFFAOYSA-N 0.000 description 2
- KDQPMQNHVQVVMR-UHFFFAOYSA-N 2-methyl-4-nitrophenol Chemical compound CC1=CC([N+]([O-])=O)=CC=C1O KDQPMQNHVQVVMR-UHFFFAOYSA-N 0.000 description 2
- AQDKZPFDOWHRDZ-UHFFFAOYSA-N 2-methyl-6-nitrophenol Chemical compound CC1=CC=CC([N+]([O-])=O)=C1O AQDKZPFDOWHRDZ-UHFFFAOYSA-N 0.000 description 2
- WFOIXZNEMLWJNK-UHFFFAOYSA-N 3,4-dimethyl-2-nitrophenol Chemical compound CC1=CC=C(O)C([N+]([O-])=O)=C1C WFOIXZNEMLWJNK-UHFFFAOYSA-N 0.000 description 2
- APRYNIRZSROXCQ-UHFFFAOYSA-N 3-ethyl-2-nitrophenol Chemical compound CCC1=CC=CC(O)=C1[N+]([O-])=O APRYNIRZSROXCQ-UHFFFAOYSA-N 0.000 description 2
- DOGIHOCMZJUJNR-UHFFFAOYSA-N 4-methyloctane Chemical compound CCCCC(C)CCC DOGIHOCMZJUJNR-UHFFFAOYSA-N 0.000 description 2
- XJNPNXSISMKQEX-UHFFFAOYSA-N 4-nitrocatechol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1O XJNPNXSISMKQEX-UHFFFAOYSA-N 0.000 description 2
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 2
- PHOJOSOUIAQEDH-UHFFFAOYSA-N 5-hydroxypentanoic acid Chemical compound OCCCCC(O)=O PHOJOSOUIAQEDH-UHFFFAOYSA-N 0.000 description 2
- VBKPPDYGFUZOAJ-UHFFFAOYSA-N 5-oxopentanoic acid Chemical compound OC(=O)CCCC=O VBKPPDYGFUZOAJ-UHFFFAOYSA-N 0.000 description 2
- IWHLYPDWHHPVAA-UHFFFAOYSA-N 6-hydroxyhexanoic acid Chemical compound OCCCCCC(O)=O IWHLYPDWHHPVAA-UHFFFAOYSA-N 0.000 description 2
- PNPPVRALIYXJBW-UHFFFAOYSA-N 6-oxohexanoic acid Chemical compound OC(=O)CCCCC=O PNPPVRALIYXJBW-UHFFFAOYSA-N 0.000 description 2
- PNAJBOZYCFSQDJ-UHFFFAOYSA-N 7-hydroxyheptanoic acid Chemical compound OCCCCCCC(O)=O PNAJBOZYCFSQDJ-UHFFFAOYSA-N 0.000 description 2
- OOFMTFUTWFAVGC-UHFFFAOYSA-N 7-oxoheptanoic acid Chemical compound OC(=O)CCCCCC=O OOFMTFUTWFAVGC-UHFFFAOYSA-N 0.000 description 2
- UEXYJHLCLUYOFA-UHFFFAOYSA-N 8-oxooctanoic acid Chemical compound OC(=O)CCCCCCC=O UEXYJHLCLUYOFA-UHFFFAOYSA-N 0.000 description 2
- WLGDDELKYAWBBL-UHFFFAOYSA-N 9-oxononanoic acid Chemical compound OC(=O)CCCCCCCC=O WLGDDELKYAWBBL-UHFFFAOYSA-N 0.000 description 2
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical compound CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 2
- 229920000305 Nylon 6,10 Polymers 0.000 description 2
- UGUYQBMBIJFNRM-OQFOIZHKSA-N [(z)-but-2-en-2-yl]benzene Chemical compound C\C=C(\C)C1=CC=CC=C1 UGUYQBMBIJFNRM-OQFOIZHKSA-N 0.000 description 2
- 230000009798 acute exacerbation Effects 0.000 description 2
- 229960000250 adipic acid Drugs 0.000 description 2
- 235000011037 adipic acid Nutrition 0.000 description 2
- 229960002255 azelaic acid Drugs 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 210000001601 blood-air barrier Anatomy 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- KSHJAFFDLKPUMT-UHFFFAOYSA-N dinitro-ortho-cresol Chemical compound CC1=C(O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O KSHJAFFDLKPUMT-UHFFFAOYSA-N 0.000 description 2
- 238000004817 gas chromatography Methods 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 150000004671 saturated fatty acids Chemical class 0.000 description 2
- 235000003441 saturated fatty acids Nutrition 0.000 description 2
- 238000004683 secondary electrospray ionisation mass spectroscopy Methods 0.000 description 2
- DXNCZXXFRKPEPY-UHFFFAOYSA-N tridecanedioic acid Chemical compound OC(=O)CCCCCCCCCCCC(O)=O DXNCZXXFRKPEPY-UHFFFAOYSA-N 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- GIANIJCPTPUNBA-QMMMGPOBSA-N (2s)-3-(4-hydroxyphenyl)-2-nitramidopropanoic acid Chemical compound [O-][N+](=O)N[C@H](C(=O)O)CC1=CC=C(O)C=C1 GIANIJCPTPUNBA-QMMMGPOBSA-N 0.000 description 1
- FMKJUUQOYOHLTF-OWOJBTEDSA-N (e)-4-azaniumylbut-2-enoate Chemical compound NC\C=C\C(O)=O FMKJUUQOYOHLTF-OWOJBTEDSA-N 0.000 description 1
- FYURGFQVSMALOD-UHFFFAOYSA-N 10-oxocapric acid Chemical compound OC(=O)CCCCCCCCC=O FYURGFQVSMALOD-UHFFFAOYSA-N 0.000 description 1
- QZDSXQJWBGMRLU-UHFFFAOYSA-N 3-(2,3-dihydroxyphenyl)propanoic acid Chemical compound OC(=O)CCC1=CC=CC(O)=C1O QZDSXQJWBGMRLU-UHFFFAOYSA-N 0.000 description 1
- CAOVWYZQMPNAFJ-UHFFFAOYSA-N 4-(2-aminophenyl)-2,4-dioxobutanoic acid Chemical compound NC1=CC=CC=C1C(=O)CC(=O)C(O)=O CAOVWYZQMPNAFJ-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- FMKJUUQOYOHLTF-UHFFFAOYSA-N 4-Amino-2-butenoic acid Natural products NCC=CC(O)=O FMKJUUQOYOHLTF-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000018329 Keratin-18 Human genes 0.000 description 1
- 108010066327 Keratin-18 Proteins 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- JINBYESILADKFW-UHFFFAOYSA-N aminomalonic acid Chemical compound OC(=O)C(N)C(O)=O JINBYESILADKFW-UHFFFAOYSA-N 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 230000003851 biochemical process Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000001925 catabolic effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000012043 cost effectiveness analysis Methods 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 238000010972 statistical evaluation Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6848—Methods of protein analysis involving mass spectrometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6806—Determination of free amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/12—Pulmonary diseases
- G01N2800/122—Chronic or obstructive airway disorders, e.g. asthma COPD
Definitions
- the present invention relates to a method for determining whether an individual suffers from COPD (chronic obstructive pulmonary disorder), and to a computer-controlled medical diagnosis system for determining whether a individual suffers from COPD and in particular if the individual suffering from COPD additionally suffers from acute exacerbations of COPD (AECOPD).
- COPD chronic obstructive pulmonary disorder
- COPD chronic obstructive pulmonary disease
- the results from spirometry suffer from a lack of specificity and are therefore usually complemented by correlation to other symptoms indicative of COPD, such as dyspnea, chronic cough or sputum production, or to a history of exposure to risk factors. Based on the aforementioned specificity shortcomings of spirometry, a more reliable diagnostic instrument is desirable.
- Biochemical markers such as proteins have recently been used as alternative means for diagnosis of COPD.
- proteins such as interleukins, heat shock proteins, caspase-cleaved cytokeratin-18 (ccCK-18) and others requires taking samples of tissue, blood or urine, and a subsequent sample preparation that is both time-consuming and technically demanding for target proteins to be analyzed quantitatively, in most cases, through immunoassays.
- the exhaled air or breath of a patient can easily be sampled and contains certain amounts of metabolites.
- These metabolites are either produced locally in the respiratory tract itself or systemically and then released across the blood-gas barrier during gas-exchange, i.e. breathing.
- these metabolites may be useful biomarkers of the internal biochemical processes underlying COPD and serve as fast and non-invasive biomarkers in the diagnosis and monitoring of COPD, and of AECOPD in particular.
- WO2010/031788A1 discloses a method for the diagnosis of COPD, in which volatile organic carbon (VOC) compounds are detected in exhaled breath of a patient.
- VOC volatile organic carbon
- the exhaled air is collected in a bag and then lead over an absorption medium capable of trapping VOCs.
- the trapped VOCs are subsequently released through heating the absorption medium and lead into a gas chromatography capillary column and detected by a mass spectrometer equipped with a time-of-flight detector (TOF-MS).
- TOF-MS time-of-flight detector
- VOCs used as biomarkers for COPD are described such as isoprene, saturated an unsubstituted branched alkanes such as C 16H34; 4,7,- dimethyl undecane; 2,6-dimethyl heptane; 4-methyl octane and linear C i6H 34 .
- WO2010/031788A1 thus discloses a method in which VOCs are determined in stored/adsorbed breath samples using GC-MS.
- US 9 121 844 Bl discloses a method for analyzing vapors emanating from the human body, such as for example breath or skin vapors, by combining a SESI ionizer with a mass spectrometer for the purpose of classifying humans with respect to ion mass and signal intensity of the volatile or semi-volatile species comprised in said vapors.
- the disclosed method is in essence improved vis-a-vis the prior art in the sense that the data collected is made more reliable by bringing both the sample flow and the background flow to the same humidity before being sampled into the SESI ionizer. While it is disclosed that the data pair of ion mass and signal intensity can be used to recognize the state of health of a person, there is however no disclosure to be found which could be used to relate a particular medical condition to the disclosed to ion mass and/or signal intensity.
- the present invention provides for a method and computer-controlled medical diagnosis system that allows determining easily and non-invasively if an individual suffers from COPD and AECOPD by analysis of the exhaled breath of an individual, using multiple, newly-found biomarkers comprised in the exhaled breath.
- the method and computer-controlled medical diagnosis system of the present invention has the advantage of being more reliable than traditional spirometry analysis and less complex than other biomarker- based methods that require blood sampling and subsequent preparation/purification of blood samples before biomarker analysis.
- the newly-found biomarkers that can be used in the method and the computer-controlled medical diagnosis system of the present invention have been identified by correlating features comprised in the exhaled breath of control individuals and COPD patients, and measured by SESI-MS, to the FEV1 (% predicted).
- FEV1 forced expiratory volume in 1 second
- FEV1 represents the proportion of a person's vital capacity that they are able to expire in the first second of forced expiration.
- this methodology has yielded a plurality of compounds which can be used to classify for COPD / non-COPD status.
- the applicants have classified the newly-found biomarkers with respect to certain types of metabolites of biomolecules such as for example fatty acids.
- biomarkers are, in and of themselves as compounds, reliable indicators in exhaled breath that allow classifying for COPD/ non- COPD status, irrespective of their assumed or true metabolic or catabolic origin.
- any teaching relative to a group of metabolites or individual metabolites should be considered to apply to the individual compounds themselves as enumerated within the group of metabolites, unless indicated otherwise.
- determining if the presence, absence or relative concentration of said metabolites is indicative of COPD or AECOPD by comparing the determined presence, absence or relative concentration of at least two metabolites to predetermined reference values, characterized in that the metabolites are chosen from the group of metabolites of amino acids, in particular of proteinogenic amino acids, from the group of metabolites emanating from of an oxidative or carbonyl stress process such as ⁇ -oxidation products of linear aliphatic fatty acids, from the group of metabolites emanating from nitrosative stress such as nitrophenol derivatives or from combinations of said groups, optionally together with pyridine and/or uric acid and/or fucose and/or 4-aminobenezene-l ,2-diol.
- determining if the presence, absence or relative concentration of said compounds is indicative of COPD or AECOPD by comparing the determined presence, absence or relative concentration of at least two compounds to predetermined reference values, characterized in that the compounds are chosen from dehydroalanine, 2-oxoglutaric acid semialdehyde, aspartic acid semialdehyde, ⁇ -hydroxyalkanoic acids (C X H2 X 0 3 ) such as 5- hydroxypentanoic acid, 6-hydroxyhexanoic acid, 7-hydroxyheptanoic acid, 8- hydroxyoctanoic acid, 9-hydroxynonanoic acid, 10-hydroxydecanoic acid, 11- hydroxyundecanoic acid, 12-hydroxydodecanoic acid, 13-hydroxytridecanoic acid, 14- hydroxytetradecanoic acid, 15-hydroxypentadecanoic acid, ⁇ -oxoalkanoic acids such as 5- oxopentanoic acid, 6-ox, as
- a. a computer and a mass spectrometer wherein the mass spectrometer comprises i. an ionization chamber and an inlet fluidly connected to the ionization chamber for providing a sample to said ionization chamber, and
- a mass analysis and detector device capable of detecting metabolites and a data line connecting the mass analysis and detector device to a computer for providing data to the computer
- processing said data such as to simultaneously determine the presence, absence or relative concentration of at least two metabolites in said sample on the basis of the data provided to said computer;
- the at least two metabolites are chosen from the group of metabolites of amino acids, from the group of metabolites emanating from of an oxidative or carbonyl stress process such as ⁇ -oxidation products of linear fatty acids, from the group of metabolites emanating from nitrosative stress such as nitrophenol derivatives, or from combinations of the metabolites of said groups optionally together with pyridine and/or uric acid and/or fucose and/or 4-aminobenezene-l,2-diol.
- Fig. 1 shows a schematic representation of a computer-controlled medical diagnosis system comprising a mouthpiece (2), through which a test subject (1) can exhale breath into the heated PTFE tube (3), where the pressure in the heated PTFE tube (3) is controlled using a digital manometer (4).
- the heated PTFE tube (3) is fluidly connected to the ionization chamber (9) of the ionization source (5) such as to allow the flow of heated breath (10) to enter the ionization chamber (9), where a nano electrospray nozzle (8) generates a nano electrospray plume (12) which ionizes the heated breath
- Fig. 2a, 2b shows a mass spectrum of the breath of a healthy control (top, 2a) and a mass spectrum of the breath of a COPD patient (bottom, 2b).
- the section corresponding of C5N5H, C 8 H 2 2N 6 02 and Ci 7 H 32 03 is shown enlarged in the respective, annotated boxes.
- the peak corresponding to C5N5H displays a roughly two-fold increase in intensity in the COPD patients when compared to healthy controls whereas the peaks corresponding to C8H22N6O2 and Ci 7 H 3 20 3 display a relative decrease in intensity in in the COPD patients when compared to healthy controls.
- Fig. 3a - 3f shows the receiver operating characteristic (ROC) according to the present invention and from multiple scientific publications, which are described in more detail below.
- ROC receiver operating characteristic
- the present invention provides a method for determining whether an individual suffers from a disease of the lower respiratory tract such as COPD or AECOPD, said method comprising the step of:
- determining if the presence, absence or relative concentration of said metabolites is indicative of COPD by comparing the determined presence, absence or relative concentration of said at least two metabolites to predetermined reference values, characterized in that the metabolites are chosen from the group of metabolites of amino acids, from the group of metabolites emanating from of an oxidative or carbonyl stress process such as ⁇ -oxidation products of linear fatty acids, from the group of metabolites emanating from nitrosative stress such as nitrophenol derivatives, or from combinations of the metabolites from said groups, optionally together with pyridine and/or uric acid and/or fucose and/or 4-aminobenezene-l,2-diol.
- the at least two metabolites of which the presence, absence or relative concentration is determined can be chosen from the same group of metabolites (e.g. solely from co-oxidation products of linear fatty acids) or from different groups of metabolites.
- one or more metabolites of the at least two metabolites of which the presence, absence or relative concentration is determined is chosen from pyridine and/or uric acid and/or fucose and/or 4- aminobenezene-l ,2-diol
- the remaining metabolites of which the presence, absence or relative concentration is determined can likewise be chosen from the same group of metabolites (e.g. solely from co-oxidation products of linear fatty acids) or from different groups of metabolites.
- the present invention provides a method for determining whether an individual suffers from a disease of the lower respiratory tract such as COPD or AECOPD, said method comprising the step of:
- the sample can consist either of as-is exhaled breath of the individual for which the determination of whether or not he or she suffers from COPD or AECOPD is to be carried out, or it may comprise exhaled breath in combination with other inert substances.
- the exhaled breath is comprised in an analytical matrix such as for example an inert gaseous matrix
- the sample consists of neat exhaled breath, i.e. without the admixture of another substance, since it is possible that for example the matrix, even though it should be inert, can provoke a chemical change in the metabolites of the exhaled breath.
- the sample is formed by at least a part of an exhaled breath flow of the individual. This is achieved by redirecting at least part of a breath flow being exhaled directly into the ionization chamber of the mass spectrometer.
- a mouth piece or face mask that is fluidly connected to an inlet of the ionization chamber of the mass spectrometer can be used.
- the mouth piece connected to the inlet can be sealed by the lips of the individual whereas the face mask can be fitted to the face of the patient in an air sealing manner.
- the flow of exhaled breath can be controlled by for example monitoring the pressure in a connection means fluidly connecting the mouthpiece or face mask to the inlet, such as a PTFE tube, using a manometer.
- the temperature and humidity of the flow of exhaled breath may be controlled, for example by heating the exhaled breath to a predetermined temperature and adjusting the relative humidity of the exhaled breath, in order to provide for the same conditions in each sample analysis.
- the sample is formed by redirecting at least part of the final 50% by volume, or final 25% by volume, of the exhaled breath flow of said patient into the ionization chamber of the mass spectrometry device.
- the sample should contain the part of the exhaled breath which best reflects the composition of the breath at the blood-air barrier, i.e. the alveolar breath.
- the alveolar breath is released towards the later part of a single exhalation, and thus it is preferable that the sample be formed by the final 50% by volume, or final 25% by volume, of the exhaled breath flow.
- This may be for example achieved by selectively redirecting the breath through the use of a valve system that allows splitting the exhaled breath into the corresponding final volume fractions.
- the patient may be directed to only exhale the latter part of his exhaled breath into a mouthpiece fluidly connected to the ionization chamber.
- the individual fasts overnight to minimize interferences coming from the mouth and obtain a repeatable breath pattern.
- the sample comprises, or consists of, exhaled breath condensate (EBC).
- EBC exhaled breath condensate
- Using a sample of exhaled breath condensate can be useful in the case where the patient, for either medical or practical reasons, is not able to be brought into the proximity of the mass spectrometer.
- a person skilled in the art will know how to collect exhaled breath concentrate, since multiple publications relating to the analysis of EBC exist.
- the metabolites of amino acids are in particular metabolites of nonpolar amino acids such as glycine, alanine, phenylalanine, proline valine, isoleucine and leucine, metabolites polar amino acids such as lysine, ornithine, glutamic acid, aspartic acid, serine or cysteine.
- nonpolar amino acids such as glycine, alanine, phenylalanine, proline valine, isoleucine and leucine
- metabolites polar amino acids such as lysine, ornithine, glutamic acid, aspartic acid, serine or cysteine.
- the amino acids diffuse across the blood-air barrier and are exhaled with the breath. Therefore, the presence, absence or concentration of these amino acids and their corresponding metabolites can be detected with suitable methods such as mass spectrometry and can be assigned to a medical condition, in particular COPD.
- Metabolites of amino acids that have been identified in the context of the present invention as being indicative for COPD are, without wishing to be limited, dehydroalanine, 2- oxoglutaric acid semialdehyde, and aspartic acid semialdehyde.
- the group of metabolites of an oxidative or carbonyl stress process consists of ⁇ -oxidation products of linear fatty acids.
- ⁇ -oxidation products of linear fatty acids are co- hydroxyalkanoic acids ( ⁇ ⁇ ⁇ 2 ⁇ ⁇ 3), co-oxoalkanoic acids (C x H2 X -20 3 ) or alkanedioic acids (C x H2x -2 0 ).
- the aforementioned metabolites of linear fatty acids are metabolites of C5-C15 linear fatty acids.
- Examples of ⁇ -hydroxyalkanoic acids are 5-hydroxypentanoic acid, 6-hydroxyhexanoic acid, 7-hydroxyheptanoic acid, 8-hydroxyoctanoic acid, 9-hydroxynonanoic acid, 10-hydroxydecanoic acid, 11- hydroxyundecanoic acid, 12-hydroxydodecanoic acid, 13-hydroxytridecanoic acid, 14- hydroxytetradecanoic acid, 15-hydroxypentadecanoic acid.
- suitzable co- oxoalkanoic acids are 5-oxopentanoic acid, 6-oxohexanoic acid, 7-oxoheptanoic acid, 8- oxooctanoic acid, 9-oxononanoic acid, 10-oxodecaiioic acid, 11-oxoundecanoic acid, 12- oxododecanoic acid, 13-oxotridecanoic acid, 14-oxotetradecanoic acid, 15- oxopentadecanoic acid.
- alkanedioic acids examples include pentanedioic acid, hexanedioic acid, heptanedioic acid, octanedioic acid, nonanedioic acid, decanedioic acid, undecanedioic acid, dodecanedioic acid, tridecanedioic acid, tetradecanedioic acid, pentadecanedioic acid.
- the co- oxidation products of linear fatty acids allow further to discriminate between COPD patients and patients suffering from acute exacerbation of COPD (AECOPD).
- a patient suffering from AECOPD will exhibit a decreased relative concentration of co-oxidation products of linear aliphatic fatty acids audi as co-hydroxyalkanoic acids (C x H 2x 0 3 ), co- oxoalkanoic acids (C x H 2x-2 03) or alkanedioic acids (C x H 2 x- 2 04) when compared to healthy individuals.
- a decreased relative concentration of co-hydroxyalkanoic acids (C x H 2 x0 3 ), co-oxoalkanoic acids (C x H 2x . 2 03) or alkanedioic acids (C x H 2x-2 04) is not only indicative of COPD but in particular is further indicative of AECOPD.
- the group of metabolites emanating from nitrosative stress includes nitrophenol derivatives such as for example nitrotyrosine and nitrophenol derivatives such as nitrohydroquinones, dinitrophenols, nitrocatechols and alkylated derivatives thereof.
- nitrophenol derivatives such as for example nitrotyrosine
- nitrophenol derivatives such as nitrohydroquinones, dinitrophenols, nitrocatechols and alkylated derivatives thereof.
- dimethylnitrophenol, ethylnitrophenol, 2-methyl-3,5-dinitrophenol, 2,4-dinitrophenol, 2,5- dinitrophenol, 2-nitrohydroquinone, 4-nitrocatechol, 2-methyl-4-nitrophenol, 2-methyl-6- nitrophenol and 4-nitrophenol have been found to be indicative of COPD but in particular are further indicative of AECOPD.
- the metabolites of an oxidative or carbonyl stress process are derivatives of fatty acids, saturated or unsaturated, such as medium-chain fatty acids, long-chain fatty acids or very long-chain fatty acids, which are preferably hydroxylated, carbonylated or carboxylated derivatives thereof.
- a class of compounds that show particular promise as indicators of COPD are hydroxy- or keto-derivatives of fatty acids, especially of long- or medium-chain fatty acids, such as the above-mentioned ⁇ -oxidation products of linear C5-C15 fatty acids. For instance, it has been found that hydroxylated, carbonylated or carboxylated derivatives of saturated fatty acids are particularly useful.
- Metabolites emanating from of an oxidative or carbonyl stress process that have been identified in the context of the present invention as being indicative of COPD are, without wishing be limited to the following substances, hydroxyisobutyric acid, acetohydroxybutanoic acid, hydroxyundecanoic acid, oxo-tetradecenoic acid, hexadecatrienoic acid, oxo-heptadecanoic acid, hydroxyalkanaoic acid, 4-2-aminophenyl- 2,4-dioxobutanoic acid, oxoalkenoic acid, dodecanedioic acid, oxotetradecandioic acid, oxoalkanoic acid, 4-oxobutainoic acid, 2-aminomalonic acid semi-aldehyde, 4-amino-2 butenoic acid, 2-oxoglutaric acid semialdehyde, 2-amino-4-oxobutanoic acid,
- metabolites emanating from an oxidative or carbonyl stress process include the above-mentioned oxidation products of aliphatic fatty acids, preferably of aliphatic linear fatty acids have been found to be indicative of COPD.
- the presence, absence or relative concentration of more than at least two metabolites can be determined.
- the at least two metabolites can either be solely chosen from one of the groups or from any combination of groups, i.e.
- the group of metabolites of amino acids the group of metabolites emanating from of an oxidative or carbonyl stress process such as co-oxidation products of linear fatty acids, the group of metabolites emanating from nitrosative stress or from combinations of the metabolites of said groups, optionally together with pyridine and/or uric acid and/or fucose and/or 4-aminobenezene-l,2-diol.
- the detected relative concentration of a metabolite may increase or decrease in the case of COPD.
- pyridine is present in higher amounts in the breath of COPD patients when compared to healthy controls, whereas derivatives of saturated fatty acids such as oxo-heptadecanoic acid are present in lower amounts in the breath of COPD patients, when compared to healthy controls.
- the present invention further provides a computer-controlled medical diagnosis system for determining whether an individual suffers from a disease of the lower respiratory tract such as COPD or AECOPD, comprising a computer and a mass spectrometer, wherein the mass spectrometer comprises i. an ionization chamber and an inlet fluidly connected to the ionization chamber for providing a sample to said ionization chamber, and ii. a mass analysis and detector device capable of detecting metabolites and a data line connecting the mass analysis and detector device to a computer for providing data to the computer, wherein the computer is configured for i. receiving data provided by the mass analysis and detector device to the computer using the data line and, ii.
- a computer-controlled medical diagnosis system for determining whether an individual suffers from a disease of the lower respiratory tract such as COPD or AECOPD, comprising a computer and a mass spectrometer, wherein the mass spectrometer comprises i. an ionization chamber and an inlet fluidly connected to the ionization
- processing said data such as to simultaneously determine the presence, absence or relative concentration of at least two metabolites in said sample on the basis of the data provided to said computer; iii. comparing the determined presence, absence or relative concentration of at least two metabolites in said sample to predetermined reference values for said at least two metabolites, characterized in that the at least two metabolites are chosen from the group of metabolites of amino acids, from the group of metabolites emanating from of an oxidative or carbonyl stress process such co-oxidation products of linear fatty acids, from the group of metabolites emanating from nitrosative stress such as nitrophenol derivatives, or from combinations of the metabolites of said groups optionally together with pyridine and/or uric acid and/or fucose and/or 4-aminobenezene-l,2-diol.
- the mass spectrometer comprises ionization chamber and an inlet fluidly connected to the ionization chamber for providing a sample to said ionization chamber, and a mass analysis and detector device capable of detecting metabolites and a data line connecting the mass analysis and detector device to a computer for providing data to the computer.
- the sample can be a flow of exhaled breath, which is preferably adjusted to a given temperature, humidity and/or pressure.
- the computer is configured for i. receiving data provided by the mass analysis and detector device to the computer using the data line and, ii. processing said data such as to simultaneously determine the presence, absence or relative concentration of at least two metabolites in said sample on the basis of the data provided to said computer; iii. comparing the determined presence, absence or relative concentration of at least two metabolites in said sample to predetermined reference values for said at least two metabolites.
- the computer can be configured for example by providing it with an appropriate software package that enables a user to set the masses, or ranges of masses, that correspond to the at least two metabolites that are to be qualitatively and quantitatively detected.
- the software package allows the computer to process the data received from the detector such as to simultaneously determine the presence, absence or relative concentration of at least two metabolites in said sample on the basis of the data provided to said computer.
- the determined presence, absence or relative concentration can then be compared to predetermined reference values for said at least two metabolites by either displaying the comparison result in the form of a table or graph, or a score for example.
- the predetermined reference values for the presence, absence or relative concentration of at least two metabolites can be collected by determining the presence, absence or relative concentration of the at least two metabolites of interest in a population of control individuals not suffering from COPD or AECOPD and computing a range or threshold value for the at least two metabolites that allows to separate a healthy individual from an individual suffering from COPD or AECOPD with sufficient significance.
- the experimental setup consists of a high-resolution mass spectrometer modified to allow for the admission of breath sample through a heated tube made from an inert material. Exhaled breath is mixed with a nano electrospray plume (water and 0.2% formic acid) whereby some compounds can be detected in real time.
- the mass spectrometer can be operated in positive or negative ion mode. The subjects are instructed to provide a deep exhalation through a disposable mouth piece, while keeping the pressure through the sampling tube at 20 mbar (monitored by digital manometer), thereby ensuring that each subject breathed at the approximate same flow rate of 1.8 1/min. This process is repeated several times per subject, with typically 6 replicate measurements, taking less than 6 min.
- the setup is shown in Figure 1.
- Figure 3a shows the result classification based on a statistical evaluation of all detected compounds according to the present invention, a so-called receiver operating characteristic (ROC) curve.
- ROC receiver operating characteristic
- the compounds are enumerated in Table 1 , below.
- the data was collected from 22 patients with COPD and 14 healthy controls. The two groups were balanced concerning age, gender, smoking state, pack-years and body mass index.
- the area under curve (AUC) is 0.92.
- Figure 3 b shows the receiver operating characteristic (ROC) curve based on the findings described in Thorn J, Tilling B, Lisspers K, Jorgensen L, Stenling A, Stratelis G. Improved prediction of COPD in at-risk patients using lung function pre-screening in primary care: a real-life study and cost-effectiveness analysis.
- Thorn et al. attempted to discriminate between COPD patients and healthy controls through the ratio between FEVi/FEV 6 .
- the area under curve (AUC) is 0.84.
- Figure 3c shows the receiver operating characteristic (ROC) curve based on the findings described in Stanley AJ, Hasan I, Crockett AJ, van Schayck OCP, Zwar NA. Validation of the COPD Diagnostic Questionnaire in an Australian general practice cohort: a cross- sectional study. Prim Care Respir J. 2014;23(l):92-97. doi: 10.4104/pcrj.2014.00015 Stanley et al. attempted to discriminate between COPD patients and healthy controls through a COPD diagnostic questionnaire. The area under curve (AUC) is 0.71.
- Figure 3d shows the receiver operating characteristic (ROC) curve based on the findings described in Martinez FJ, Raczek AE, Seifer FD, et al. Development and initial validation of a self-scored COPD Population Screener Questionnaire (COPD-PS). COPD.
- COPD receiver operating characteristic
- Figure 3e shows the receiver operating characteristic (ROC) curve based on the findings described in Kon SSC, Canavan JL, Jones SE, et al. Minimum clinically important difference for the COPD Assessment Test: a prospective analysis. Lancet Respir Med. 2014;2(3): 195-203. doi : 10.1016/S2213 -2600( 14)70001-3 Kon et al. attempted to discriminate between COPD patients and healthy controls through a score derived from a "St George's respiratory questionnaire".
- the area under curve (AUC) is 0.65.
- Figure 3f shows the receiver operating characteristic (ROC) curve based on the findings described in Kon SSC, Canavan JL, Jones SE, et al. Minimum clinically important difference for the COPD Assessment Test: a prospective analysis. Lancet Respir Med. 2014;2(3): 195-203. doi: 10.1016/S2213-2600( 14)70001 -3 Kon et al. attempted to discriminate between COPD patients and healthy controls through a score derived from a chronic respiratory questionnaire. The area under curve (AUC) is 0.70.
- AUC area under curve
- the area under curve (AUC) is 0.92, which is the highest value amongst Figures 3a, 3b, 3c, 3d, 3e and 3f. This indicates an increased sensitivity and specificity for the method according to the present invention, when compared with methods relying on traditional forced expiratory volume
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Endocrinology (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Abstract
The present invention provides a method for determining whether a patient suffers from COPD, said method comprising the step of: a. providing at a sample comprising, or consisting of, exhaled breath of said patient to an ionization chamber of a mass spectrometer; b. simultaneously determining the presence, absence or relative concentration of at least two metabolites in said sample using said mass spectrometer; c. determining if the presence, absence or relative concentration of said metabolites is indicative of COPD by comparing the determined presence, absence or relative concentration of at least two metabolites to predetermined reference values, characterized in that the metabolites are chosen from the group of metabolites of amino acids, metabolites emanating from of an oxidative or carbonyl stress process, or from combinations of said groups, optionally together with pyridine.
Description
TITLE METHOD OF DETECTING COPD BY MASS SPECTROMETRY
TECHNICAL FIELD
The present invention relates to a method for determining whether an individual suffers from COPD (chronic obstructive pulmonary disorder), and to a computer-controlled medical diagnosis system for determining whether a individual suffers from COPD and in particular if the individual suffering from COPD additionally suffers from acute exacerbations of COPD (AECOPD).
PRIOR ART
Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide. Diagnosis is currently based on fixed airflow limitation in spirometry, respiratory symptoms and an appropriate history of exposure to risk factors. However, extensive training on how to perform and interpret spirometry has to be done to guarantee adequate disease assessment by medical personnel. While spirometry can help identifying the disease at a stage at which breathing symptoms arise, it is inherently unsuited for use in the diagnosis of the early stages of COPD, where breathing symptoms might be absent. Also, because of the breathing symptoms can potentially be caused by other diseases of the respiratory tract, such as asthma, the results from spirometry suffer from a lack of specificity and are therefore usually complemented by correlation to other symptoms indicative of COPD, such as dyspnea, chronic cough or sputum production, or to a history of exposure to risk factors. Based on the aforementioned specificity shortcomings of spirometry, a more reliable diagnostic instrument is desirable.
Biochemical markers such as proteins have recently been used as alternative means for diagnosis of COPD. However, the use of proteins such as interleukins, heat shock proteins,
caspase-cleaved cytokeratin-18 (ccCK-18) and others requires taking samples of tissue, blood or urine, and a subsequent sample preparation that is both time-consuming and technically demanding for target proteins to be analyzed quantitatively, in most cases, through immunoassays.
The exhaled air or breath of a patient, on the other hand, can easily be sampled and contains certain amounts of metabolites. These metabolites are either produced locally in the respiratory tract itself or systemically and then released across the blood-gas barrier during gas-exchange, i.e. breathing. As such, these metabolites may be useful biomarkers of the internal biochemical processes underlying COPD and serve as fast and non-invasive biomarkers in the diagnosis and monitoring of COPD, and of AECOPD in particular.
WO2010/031788A1 discloses a method for the diagnosis of COPD, in which volatile organic carbon (VOC) compounds are detected in exhaled breath of a patient. The exhaled air is collected in a bag and then lead over an absorption medium capable of trapping VOCs. The trapped VOCs are subsequently released through heating the absorption medium and lead into a gas chromatography capillary column and detected by a mass spectrometer equipped with a time-of-flight detector (TOF-MS). A problem with such methodology and/or set-up is that the heating of the absorption medium and of the gas chromatography column can in some cases result in fragmentation of the compounds comprised in the exhaled breath, thereby making it impossible to determine some of the more thermally fragile compounds. The VOCs used as biomarkers for COPD are described such as isoprene, saturated an unsubstituted branched alkanes such as C 16H34; 4,7,- dimethyl undecane; 2,6-dimethyl heptane; 4-methyl octane and linear C i6H34. WO2010/031788A1 thus discloses a method in which VOCs are determined in stored/adsorbed breath samples using GC-MS.
US 9 121 844 Bl discloses a method for analyzing vapors emanating from the human body, such as for example breath or skin vapors, by combining a SESI ionizer with a mass spectrometer for the purpose of classifying humans with respect to ion mass and signal intensity of the volatile or semi-volatile species comprised in said vapors. The disclosed method is in essence improved vis-a-vis the prior art in the sense that the data collected is made more reliable by bringing both the sample flow and the background flow to the same
humidity before being sampled into the SESI ionizer. While it is disclosed that the data pair of ion mass and signal intensity can be used to recognize the state of health of a person, there is however no disclosure to be found which could be used to relate a particular medical condition to the disclosed to ion mass and/or signal intensity.
It is thus desirable to provide a method that allows determining almost instantly if a person suffers from COPD or AECOPD on the basis of alternative biomarkers with high and specificity and sensitivity.
SUMMARY OF THE INVENTION
The present invention provides for a method and computer-controlled medical diagnosis system that allows determining easily and non-invasively if an individual suffers from COPD and AECOPD by analysis of the exhaled breath of an individual, using multiple, newly-found biomarkers comprised in the exhaled breath. The method and computer- controlled medical diagnosis system of the present invention has the advantage of being more reliable than traditional spirometry analysis and less complex than other biomarker- based methods that require blood sampling and subsequent preparation/purification of blood samples before biomarker analysis. The newly-found biomarkers that can be used in the method and the computer-controlled medical diagnosis system of the present invention have been identified by correlating features comprised in the exhaled breath of control individuals and COPD patients, and measured by SESI-MS, to the FEV1 (% predicted). FEV1 (forced expiratory volume in 1 second) represents the proportion of a person's vital capacity that they are able to expire in the first second of forced expiration. In total, this methodology has yielded a plurality of compounds which can be used to classify for COPD / non-COPD status. Without wishing to be held to a particular theory, the applicants have classified the newly-found biomarkers with respect to certain types of metabolites of biomolecules such as for example fatty acids. It is understood that the newly-found biomarkers are, in and of themselves as compounds, reliable indicators in exhaled breath that allow classifying for COPD/ non- COPD status, irrespective of their assumed or true metabolic or catabolic origin. Thus, any teaching relative to a group of metabolites or individual metabolites should be considered to apply to the individual compounds themselves as enumerated within the group of metabolites, unless indicated otherwise.
Accordingly, it is an object of the present invention to provide a method for determining whether a patient suffers from a disease of the lower respiratory tract such as COPD or
AECOPD, said method comprising the step of:
a. providing at a sample comprising, or consisting of, exhaled breath of said patient to an ionization chamber of a mass spectrometer;
b. simultaneously determining the presence, absence or relative concentration of at least two metabolites in said sample using said mass spectrometer;
c. determining if the presence, absence or relative concentration of said metabolites is indicative of COPD or AECOPD by comparing the determined presence, absence or relative concentration of at least two metabolites to predetermined reference values, characterized in that the metabolites are chosen from the group of metabolites of amino acids, in particular of proteinogenic amino acids, from the group of metabolites emanating from of an oxidative or carbonyl stress process such as ω-oxidation products of linear aliphatic fatty acids, from the group of metabolites emanating from nitrosative stress such as nitrophenol derivatives or from combinations of said groups, optionally together with pyridine and/or uric acid and/or fucose and/or 4-aminobenezene-l ,2-diol.
It is an alternative object of the present invention to provide a method for determining whether a patient suffers from a disease of the lower respiratory tract such as COPD or AECOPD, said method comprising the step of:
a. providing at a sample comprising, or consisting of, exhaled breath of said patient to an ionization chamber of a mass spectrometer;
b. simultaneously determining the presence, absence or relative concentration of at least two compounds in said sample using said mass spectrometer;
c. determining if the presence, absence or relative concentration of said compounds is indicative of COPD or AECOPD by comparing the determined presence, absence or relative concentration of at least two compounds to predetermined reference values, characterized in that the compounds are chosen from dehydroalanine, 2-oxoglutaric acid semialdehyde, aspartic acid semialdehyde, ω-hydroxyalkanoic acids (CXH2X03) such as 5- hydroxypentanoic acid, 6-hydroxyhexanoic acid, 7-hydroxyheptanoic acid, 8- hydroxyoctanoic acid, 9-hydroxynonanoic acid, 10-hydroxydecanoic acid, 11- hydroxyundecanoic acid, 12-hydroxydodecanoic acid, 13-hydroxytridecanoic acid, 14- hydroxytetradecanoic acid, 15-hydroxypentadecanoic acid, ω-oxoalkanoic acids such as 5- oxopentanoic acid, 6-oxohexanoic acid, 7-oxoheptanoic acid, 8-oxooctanoic acid, 9- oxononanoic acid, 10-oxodecanoic acid, 1 1-oxoundecanoic acid, 12-oxododecanoic acid,
13-oxotridecanoic acid, 14-oxotetradecanoic acid, 15-oxopentadecanoic acid, alkanedioic acids such as pentanedioic acid, hexanedioic acid, heptanedioic acid, octanedioic acid, nonanedioic acid, decanedioic acid, undecanedioic acid, dodecanedioic acid, tridecanedioic acid, tetradecanedioic acid, pentadecanedioic acid, niti tyrosine, dimethylnitrophenol, ethylnitrophenol, 2-methyl-3,5-dinitrophenol, 2,4-dinitrophenol, 2,5-dinitrophenol, 2- nitrohydroquinone, 4-nitrocatechol, 2-methyl-4-nitrophenol, 2-methyl-6-nitrophenol and 4- nitrophenol, pyridine, uric acid, fucose, 4-aminobenezene-l ,2-diol.
It is further an object to provide a computer-controlled medical diagnosis system for determining whether an individual suffers from a disease of the lower respiratory tract such as COPD or AECOPD, comprising
a. a computer and a mass spectrometer, wherein the mass spectrometer comprises i. an ionization chamber and an inlet fluidly connected to the ionization chamber for providing a sample to said ionization chamber, and
ii. a mass analysis and detector device capable of detecting metabolites and a data line connecting the mass analysis and detector device to a computer for providing data to the computer
b. wherein the computer is configured for
i. receiving data provided by the mass analysis and detector device to the computer using the data line and,
ii. processing said data such as to simultaneously determine the presence, absence or relative concentration of at least two metabolites in said sample on the basis of the data provided to said computer;
iii. comparing the determined presence, absence or relative concentration of at least two metabolites in said sample to predetermined reference values for said at least two metabolites, characterized in that the at least two metabolites are chosen from the group of metabolites of amino acids, from the group of metabolites emanating from of an oxidative or carbonyl stress process such as ω-oxidation products of linear fatty acids, from the group of metabolites emanating from nitrosative stress such as nitrophenol derivatives, or from combinations of the metabolites of said groups optionally together with pyridine and/or uric acid and/or fucose and/or 4-aminobenezene-l,2-diol.
Further embodiments of the invention are laid down in the dependent claims.
BRIEF DESCRIPTION OF THE DRAWINGS
Preferred embodiments of the invention are described in the following with reference to the drawings, which are for the purpose of illustrating the present preferred embodiments of the invention and not for the purpose of limiting the same. In the drawings,
Fig. 1 shows a schematic representation of a computer-controlled medical diagnosis system comprising a mouthpiece (2), through which a test subject (1) can exhale breath into the heated PTFE tube (3), where the pressure in the heated PTFE tube (3) is controlled using a digital manometer (4). The heated PTFE tube (3) is fluidly connected to the ionization chamber (9) of the ionization source (5) such as to allow the flow of heated breath (10) to enter the ionization chamber (9), where a nano electrospray nozzle (8) generates a nano electrospray plume (12) which ionizes the heated breath
(13) and redirects it towards the interface (1 1) of the mass spectrometer (6). Excess breath is removed from the ionization chamber via an excess breath outlet (14). The measurement and data analysis computer is connected to the mass spectrometer (6).
Fig. 2a, 2b shows a mass spectrum of the breath of a healthy control (top, 2a) and a mass spectrum of the breath of a COPD patient (bottom, 2b). In both mass spectra (2a, 2b), the section corresponding of C5N5H, C8H22N602 and Ci7H3203 is shown enlarged in the respective, annotated boxes. As can be seen, the peak corresponding to C5N5H displays a roughly two-fold increase in intensity in the COPD patients when compared to healthy controls whereas the peaks corresponding to C8H22N6O2 and Ci7H3203 display a relative decrease in intensity in in the COPD patients when compared to healthy controls.
Fig. 3a - 3f shows the receiver operating characteristic (ROC) according to the present invention and from multiple scientific publications, which are described in more detail below.
DESCRIPTION OF PREFERRED EMBODIMENTS
The present invention provides a method for determining whether an individual suffers from a disease of the lower respiratory tract such as COPD or AECOPD, said method comprising the step of:
a. providing a sample comprising, or consisting of, exhaled breath of said individual to an ionization chamber of a mass spectrometer;
b. simultaneously determining the presence, absence or relative concentration of at least two metabolites in said sample using said mass spectrometer;
c. determining if the presence, absence or relative concentration of said metabolites is indicative of COPD by comparing the determined presence, absence or relative concentration of said at least two metabolites to predetermined reference values, characterized in that the metabolites are chosen from the group of metabolites of amino acids, from the group of metabolites emanating from of an oxidative or carbonyl stress process such as ω-oxidation products of linear fatty acids, from the group of metabolites emanating from nitrosative stress such as nitrophenol derivatives, or from combinations of the metabolites from said groups, optionally together with pyridine and/or uric acid and/or fucose and/or 4-aminobenezene-l,2-diol. It is understood that the at least two metabolites of which the presence, absence or relative concentration is determined can be chosen from the same group of metabolites (e.g. solely from co-oxidation products of linear fatty acids) or from different groups of metabolites. In the case where one or more metabolites of the at least two metabolites of which the presence, absence or relative concentration is determined is chosen from pyridine and/or uric acid and/or fucose and/or 4- aminobenezene-l ,2-diol, the remaining metabolites of which the presence, absence or relative concentration is determined can likewise be chosen from the same group of metabolites (e.g. solely from co-oxidation products of linear fatty acids) or from different groups of metabolites.
In a preferred embodiment, the present invention provides a method for determining whether an individual suffers from a disease of the lower respiratory tract such as COPD or AECOPD, said method comprising the step of:
a. providing a sample comprising, or consisting of, exhaled breath of said individual to an ionization chamber of a mass spectrometer;
b. simultaneously determining the presence, absence or relative concentration of pyridine and/or uric acid and/or fucose and/or 4-aminobenezene-l,2-diol, and at least two
metabolites in said sample using said mass spectrometer;
c. determining if the presence, absence or relative concentration of pyridine and/or uric acid and/or fucose and/or 4-aminobenezene-l,2-diol and said at least two metabolites is indicative of COPD by comparing the determined presence, absence or relative concentration of pyridine and/or uric acid and/or fucose and/or 4-aminobenezene-l,2-diol and said at least two metabolites to predetermined reference values, characterized in that the metabolites are chosen from the group of metabolites of amino acids, from the group of metabolites emanating from of an oxidative or carbonyl stress process such as co-oxidation products of linear fatty acids, from the group of metabolites emanating from nitrosative stress such as nitrophenol derivatives, or from combinations of the metabolites of said groups.
In general, the sample can consist either of as-is exhaled breath of the individual for which the determination of whether or not he or she suffers from COPD or AECOPD is to be carried out, or it may comprise exhaled breath in combination with other inert substances. While it is possible that the exhaled breath is comprised in an analytical matrix such as for example an inert gaseous matrix, it is however preferred that the sample consists of neat exhaled breath, i.e. without the admixture of another substance, since it is possible that for example the matrix, even though it should be inert, can provoke a chemical change in the metabolites of the exhaled breath.
In a preferred embodiment of the method of the present invention, the sample is formed by at least a part of an exhaled breath flow of the individual. This is achieved by redirecting at least part of a breath flow being exhaled directly into the ionization chamber of the mass spectrometer. In order to redirect the breath flow into the ionization chamber, a mouth piece or face mask that is fluidly connected to an inlet of the ionization chamber of the mass spectrometer can be used. For instance, the mouth piece connected to the inlet can be sealed by the lips of the individual whereas the face mask can be fitted to the face of the patient in an air sealing manner. In preferred embodiment, the flow of exhaled breath can be controlled by for example monitoring the pressure in a connection means fluidly connecting the mouthpiece or face mask to the inlet, such as a PTFE tube, using a manometer. Further, the temperature and humidity of the flow of exhaled breath may be
controlled, for example by heating the exhaled breath to a predetermined temperature and adjusting the relative humidity of the exhaled breath, in order to provide for the same conditions in each sample analysis. In a yet another preferred embodiment of the method of the present invention, the sample is formed by redirecting at least part of the final 50% by volume, or final 25% by volume, of the exhaled breath flow of said patient into the ionization chamber of the mass spectrometry device. The reason for this is that in context of the present invention, the sample should contain the part of the exhaled breath which best reflects the composition of the breath at the blood-air barrier, i.e. the alveolar breath. The alveolar breath is released towards the later part of a single exhalation, and thus it is preferable that the sample be formed by the final 50% by volume, or final 25% by volume, of the exhaled breath flow. This may be for example achieved by selectively redirecting the breath through the use of a valve system that allows splitting the exhaled breath into the corresponding final volume fractions. Alternatively the patient may be directed to only exhale the latter part of his exhaled breath into a mouthpiece fluidly connected to the ionization chamber. Preferably the individual fasts overnight to minimize interferences coming from the mouth and obtain a repeatable breath pattern. In an alternative embodiment of the method of the present invention, the sample comprises, or consists of, exhaled breath condensate (EBC). Using a sample of exhaled breath condensate can be useful in the case where the patient, for either medical or practical reasons, is not able to be brought into the proximity of the mass spectrometer. A person skilled in the art will know how to collect exhaled breath concentrate, since multiple publications relating to the analysis of EBC exist.
In an alternative embodiment of the method of the present invention, the metabolites of amino acids are in particular metabolites of nonpolar amino acids such as glycine, alanine, phenylalanine, proline valine, isoleucine and leucine, metabolites polar amino acids such as lysine, ornithine, glutamic acid, aspartic acid, serine or cysteine. The amino acids diffuse across the blood-air barrier and are exhaled with the breath. Therefore, the presence, absence or concentration of these amino acids and their corresponding metabolites can be detected with suitable methods such as mass spectrometry and can be
assigned to a medical condition, in particular COPD.
Metabolites of amino acids that have been identified in the context of the present invention as being indicative for COPD are, without wishing to be limited, dehydroalanine, 2- oxoglutaric acid semialdehyde, and aspartic acid semialdehyde.
In an alternative embodiment of the method of the present invention, the group of metabolites of an oxidative or carbonyl stress process consists of ω-oxidation products of linear fatty acids. For instance, ω-oxidation products of linear fatty acids are co- hydroxyalkanoic acids (ΟχΗ2χθ3), co-oxoalkanoic acids (CxH2X-203) or alkanedioic acids (CxH2x-20 ). In a preferred embodiment, the aforementioned metabolites of linear fatty acids are metabolites of C5-C15 linear fatty acids. Examples of ω-hydroxyalkanoic acids (CxH2x03) are 5-hydroxypentanoic acid, 6-hydroxyhexanoic acid, 7-hydroxyheptanoic acid, 8-hydroxyoctanoic acid, 9-hydroxynonanoic acid, 10-hydroxydecanoic acid, 11- hydroxyundecanoic acid, 12-hydroxydodecanoic acid, 13-hydroxytridecanoic acid, 14- hydroxytetradecanoic acid, 15-hydroxypentadecanoic acid. Examples of suitzable co- oxoalkanoic acids are 5-oxopentanoic acid, 6-oxohexanoic acid, 7-oxoheptanoic acid, 8- oxooctanoic acid, 9-oxononanoic acid, 10-oxodecaiioic acid, 11-oxoundecanoic acid, 12- oxododecanoic acid, 13-oxotridecanoic acid, 14-oxotetradecanoic acid, 15- oxopentadecanoic acid. Examples of alkanedioic acids are pentanedioic acid, hexanedioic acid, heptanedioic acid, octanedioic acid, nonanedioic acid, decanedioic acid, undecanedioic acid, dodecanedioic acid, tridecanedioic acid, tetradecanedioic acid, pentadecanedioic acid. In addition to being metabolites indicative of COPD, the co- oxidation products of linear fatty acids allow further to discriminate between COPD patients and patients suffering from acute exacerbation of COPD (AECOPD). A patient suffering from AECOPD will exhibit a decreased relative concentration of co-oxidation products of linear aliphatic fatty acids audi as co-hydroxyalkanoic acids (CxH2x03), co- oxoalkanoic acids (CxH2x-203) or alkanedioic acids (CxH2x-204) when compared to healthy individuals. Thus, a decreased relative concentration of co-hydroxyalkanoic acids (CxH2x03), co-oxoalkanoic acids (CxH2x.203) or alkanedioic acids (CxH2x-204) is not only indicative of COPD but in particular is further indicative of AECOPD.
In an alternative embodiment of the method of the present invention, the group of
metabolites emanating from nitrosative stress includes nitrophenol derivatives such as for example nitrotyrosine and nitrophenol derivatives such as nitrohydroquinones, dinitrophenols, nitrocatechols and alkylated derivatives thereof. In particular, dimethylnitrophenol, ethylnitrophenol, 2-methyl-3,5-dinitrophenol, 2,4-dinitrophenol, 2,5- dinitrophenol, 2-nitrohydroquinone, 4-nitrocatechol, 2-methyl-4-nitrophenol, 2-methyl-6- nitrophenol and 4-nitrophenol have been found to be indicative of COPD but in particular are further indicative of AECOPD.
In an alternative embodiment of the method of the present invention, the metabolites of an oxidative or carbonyl stress process are derivatives of fatty acids, saturated or unsaturated, such as medium-chain fatty acids, long-chain fatty acids or very long-chain fatty acids, which are preferably hydroxylated, carbonylated or carboxylated derivatives thereof. A class of compounds that show particular promise as indicators of COPD are hydroxy- or keto-derivatives of fatty acids, especially of long- or medium-chain fatty acids, such as the above-mentioned ω-oxidation products of linear C5-C15 fatty acids. For instance, it has been found that hydroxylated, carbonylated or carboxylated derivatives of saturated fatty acids are particularly useful.
Metabolites emanating from of an oxidative or carbonyl stress process that have been identified in the context of the present invention as being indicative of COPD are, without wishing be limited to the following substances, hydroxyisobutyric acid, acetohydroxybutanoic acid, hydroxyundecanoic acid, oxo-tetradecenoic acid, hexadecatrienoic acid, oxo-heptadecanoic acid, hydroxyalkanaoic acid, 4-2-aminophenyl- 2,4-dioxobutanoic acid, oxoalkenoic acid, dodecanedioic acid, oxotetradecandioic acid, oxoalkanoic acid, 4-oxobutainoic acid, 2-aminomalonic acid semi-aldehyde, 4-amino-2 butenoic acid, 2-oxoglutaric acid semialdehyde, 2-amino-4-oxobutanoic acid, benzoic acid, 3-(2,3-dihydroxyphenyl) propanoic acid, alkenal, oxoalkenoic acid, alkandioic acid. Thus, in general terms, metabolites emanating from an oxidative or carbonyl stress process include the above-mentioned oxidation products of aliphatic fatty acids, preferably of aliphatic linear fatty acids have been found to be indicative of COPD.
In an alternative embodiment of the method of the present invention, the presence, absence
or relative concentration of more than at least two metabolites can be determined. In order to increase both specificity and sensitivity of the method according to the present invention, it is preferable to determine at least 3, 4, 5, 6, 7, 8 , 9, 10, or more metabolites simultaneously in said sample, optionally in addition to pyridine and/or uric acid and/or fucose and/or 4-aminobenezene-l,2-diol. It is understood that the at least two metabolites can either be solely chosen from one of the groups or from any combination of groups, i.e. the group of metabolites of amino acids, the group of metabolites emanating from of an oxidative or carbonyl stress process such as co-oxidation products of linear fatty acids, the group of metabolites emanating from nitrosative stress or from combinations of the metabolites of said groups, optionally together with pyridine and/or uric acid and/or fucose and/or 4-aminobenezene-l,2-diol. In some cases, the detected relative concentration of a metabolite may increase or decrease in the case of COPD. For example, pyridine is present in higher amounts in the breath of COPD patients when compared to healthy controls, whereas derivatives of saturated fatty acids such as oxo-heptadecanoic acid are present in lower amounts in the breath of COPD patients, when compared to healthy controls. This is also true for co-oxidation products of linear fatty acids, which are present in lower amounts in the breath of COPD and AECOPD patients, when compared to healthy controls.
The present invention further provides a computer-controlled medical diagnosis system for determining whether an individual suffers from a disease of the lower respiratory tract such as COPD or AECOPD, comprising a computer and a mass spectrometer, wherein the mass spectrometer comprises i. an ionization chamber and an inlet fluidly connected to the ionization chamber for providing a sample to said ionization chamber, and ii. a mass analysis and detector device capable of detecting metabolites and a data line connecting the mass analysis and detector device to a computer for providing data to the computer, wherein the computer is configured for i. receiving data provided by the mass analysis and detector device to the computer using the data line and, ii. processing said data such as to simultaneously determine the presence, absence or relative concentration of at least two metabolites in said sample on the basis of the data provided to said computer; iii. comparing the determined presence, absence or relative concentration of at least two metabolites in said sample to predetermined reference values for said at least two metabolites, characterized in that the at least two metabolites are chosen from the group of metabolites of amino acids, from the group of metabolites emanating from of an oxidative or carbonyl stress process such co-oxidation products of linear fatty acids, from the group
of metabolites emanating from nitrosative stress such as nitrophenol derivatives, or from combinations of the metabolites of said groups optionally together with pyridine and/or uric acid and/or fucose and/or 4-aminobenezene-l,2-diol. The mass spectrometer comprises ionization chamber and an inlet fluidly connected to the ionization chamber for providing a sample to said ionization chamber, and a mass analysis and detector device capable of detecting metabolites and a data line connecting the mass analysis and detector device to a computer for providing data to the computer. The sample can be a flow of exhaled breath, which is preferably adjusted to a given temperature, humidity and/or pressure.
In a preferred embodiment of the computer-controlled medical diagnosis system of the present invention, the computer is configured for i. receiving data provided by the mass analysis and detector device to the computer using the data line and, ii. processing said data such as to simultaneously determine the presence, absence or relative concentration of at least two metabolites in said sample on the basis of the data provided to said computer; iii. comparing the determined presence, absence or relative concentration of at least two metabolites in said sample to predetermined reference values for said at least two metabolites. For the purpose of the present invention, the computer can be configured for example by providing it with an appropriate software package that enables a user to set the masses, or ranges of masses, that correspond to the at least two metabolites that are to be qualitatively and quantitatively detected. Once the masses or range of masses are set, the software package allows the computer to process the data received from the detector such as to simultaneously determine the presence, absence or relative concentration of at least two metabolites in said sample on the basis of the data provided to said computer. The determined presence, absence or relative concentration can then be compared to predetermined reference values for said at least two metabolites by either displaying the comparison result in the form of a table or graph, or a score for example. The predetermined reference values for the presence, absence or relative concentration of at least two metabolites can be collected by determining the presence, absence or relative concentration of the at least two metabolites of interest in a population of control individuals not suffering from COPD or AECOPD and computing a range or threshold value for the at least two metabolites that allows to separate a healthy individual from an
individual suffering from COPD or AECOPD with sufficient significance.
EXAMPLES
The experimental setup consists of a high-resolution mass spectrometer modified to allow for the admission of breath sample through a heated tube made from an inert material. Exhaled breath is mixed with a nano electrospray plume (water and 0.2% formic acid) whereby some compounds can be detected in real time. The mass spectrometer can be operated in positive or negative ion mode. The subjects are instructed to provide a deep exhalation through a disposable mouth piece, while keeping the pressure through the sampling tube at 20 mbar (monitored by digital manometer), thereby ensuring that each subject breathed at the approximate same flow rate of 1.8 1/min. This process is repeated several times per subject, with typically 6 replicate measurements, taking less than 6 min. The setup is shown in Figure 1.
Figure 3a shows the result classification based on a statistical evaluation of all detected compounds according to the present invention, a so-called receiver operating characteristic (ROC) curve. The compounds are enumerated in Table 1 , below. The data was collected from 22 patients with COPD and 14 healthy controls. The two groups were balanced concerning age, gender, smoking state, pack-years and body mass index. The area under curve (AUC) is 0.92.
Figure 3 b shows the receiver operating characteristic (ROC) curve based on the findings described in Thorn J, Tilling B, Lisspers K, Jorgensen L, Stenling A, Stratelis G. Improved prediction of COPD in at-risk patients using lung function pre-screening in primary care: a real-life study and cost-effectiveness analysis. Prim Care Respir J. 2012;21(2): 159-166. doi: 10.4104/pcrj.201 1.00104. Thorn et al. attempted to discriminate between COPD patients and healthy controls through the ratio between FEVi/FEV6. The area under curve (AUC) is 0.84.
Figure 3c shows the receiver operating characteristic (ROC) curve based on the findings described in Stanley AJ, Hasan I, Crockett AJ, van Schayck OCP, Zwar NA. Validation of the COPD Diagnostic Questionnaire in an Australian general practice cohort: a cross- sectional study. Prim Care Respir J. 2014;23(l):92-97. doi: 10.4104/pcrj.2014.00015 Stanley et al. attempted to discriminate between COPD patients and healthy controls through a COPD diagnostic questionnaire. The area under curve (AUC) is 0.71.
Figure 3d shows the receiver operating characteristic (ROC) curve based on the findings described in Martinez FJ, Raczek AE, Seifer FD, et al. Development and initial validation of a self-scored COPD Population Screener Questionnaire (COPD-PS). COPD.
2008;5(2):85-95. doi: 10.1080/15412550801940721 Martinez et al. attempted to discriminate between COPD patients and healthy controls through a score derived from a population screener questionnaire. The area under curve (AUC) is 0.81.
Figure 3e shows the receiver operating characteristic (ROC) curve based on the findings described in Kon SSC, Canavan JL, Jones SE, et al. Minimum clinically important difference for the COPD Assessment Test: a prospective analysis. Lancet Respir Med. 2014;2(3): 195-203. doi : 10.1016/S2213 -2600( 14)70001-3 Kon et al. attempted to discriminate between COPD patients and healthy controls through a score derived from a "St George's respiratory questionnaire". The area under curve (AUC) is 0.65.
Figure 3f shows the receiver operating characteristic (ROC) curve based on the findings described in Kon SSC, Canavan JL, Jones SE, et al. Minimum clinically important difference for the COPD Assessment Test: a prospective analysis. Lancet Respir Med. 2014;2(3): 195-203. doi: 10.1016/S2213-2600( 14)70001 -3 Kon et al. attempted to discriminate between COPD patients and healthy controls through a score derived from a chronic respiratory questionnaire. The area under curve (AUC) is 0.70.
Thus, as can be seen from the presented data, when using the method according to the present invention based on real-time mass spectrometry, the area under curve (AUC) is 0.92, which is the highest value amongst Figures 3a, 3b, 3c, 3d, 3e and 3f. This indicates an increased sensitivity and specificity for the method according to the present invention, when compared with methods relying on traditional forced expiratory volume
measurements or diagnostic questionnaires.
LIST OF REFERENCE SIGNS test subject
mouthpiece
heated PTFE tube
digital manometer
ionization source
mass spectrometer
measurement and data
analysis computer
nano electrospray nozzle
ionization chamber
flow of heated breath
mass spectrometer interface
nano electrospray plume
floe of ionized heated breath
excess breath outlet
breath inlet
Claims
1. A method for determining whether an individual suffers from a disease of the lower respiratory tract such as COPD or AECOPD, said method comprising the step of: a. providing a sample comprising, or consisting of, exhaled breath of said individual to an ionization chamber of a mass spectrometer;
b. simultaneously determining the presence, absence or relative concentration of at least two metabolites in said sample using said mass spectrometer; c. determining if the presence, absence or relative concentration of said metabolites is indicative of COPD by comparing the determined presence, absence or relative concentration of said at least two metabolites to predetermined reference values,
characterized in that the metabolites are chosen from the group of metabolites emanating from of an oxidative or carbonyl stress process such as co-oxidation products of linear fatty acids, from the group of metabolites of amino acids, from the group of metabolites emanating from nitrosative stress such as nitrophenol derivatives or from combinations of the metabolites of said groups, optionally together with pyridine and/or uric acid and/or fucose and/or 4-aminobenezene-l,2- diol.
2. The method according to claim 1, wherein the sample is provided by redirecting at least part of a breath flow of said individual being exhaled into the ionization chamber of the mass spectrometer.
3. The method according to claim 1 or 2, wherein the sample is formed by redirecting at least part of the final 50% by volume, or final 25% by volume, of the exhaled breath flow of said individual into the ionization chamber of the mass spectrometry device.
4. The method according to any preceding claim, wherein the sample comprises, or consists of, exhaled breath condensate (EBC).
5. The method according to any preceding claim, wherein the group of co-oxidation products of linear fatty acids comprises co-hydroxyalkanoic acids (CxH2x03), co- oxoalkanoic acids (CxH2x-203) or alkanedioic acids (CxH2x-204) and/or the group of
metabolites emanating from nitrosative stress such as nitrophenol derivatives includes nitrohydroquinones, dinitrophenols, nitrocatechols and alkylated derivatives thereof.
6. The method according to any preceding claim, wherein the metabolites of amino acids are in particular metabolites of nonpolar amino acids such as glycine, alanine, phenylalanine, proline valine, isoleucine and leucine, metabolites of polar amino acids such as lysine, ornithine, glutamic acid, aspartic acid, serine or cysteine.
7. The method according to claim 6, wherein the metabolites of amino acids are chosen from dehydroalanine, 2-oxoglutaric acid semialdehyde, aspartic acid semialdehyde.
8. The method according to any preceding claim, wherein the ionization chamber is configured to produce ions using an electrospray, and in particular is configured to produce ions using secondary electrospray ionization (SESI), and/or wherein the mass spectrometer is preferably a time-of-flight mass spectrometer.
9. The method according to any preceding claim, wherein the metabolites emanating from of an oxidative or carbonyl stress process are derivatives of fatty acids, saturated or unsaturated, such as medium-chain fatty acids, long-chain fatty acids or very long-chain fatty acids, which are preferably hydroxylated, carbonylated or carboxylated derivatives thereof.
10. The method according to claim 9, wherein the metabolites emanating from of an oxidative or carbonyl stress process are chosen from 2-hydroxyisobutyric acid, acetohydroxybutanoic acid, hydroxyundecanoic acid, oxo-tetradecenoic acid, hexadecatrienoic acid, oxo-heptadecanoic acid.
1 1. The method according to any preceding claim, wherein the presence, absence or relative concentration of at least 3, 4, 5, 6, 7, 8 , 9, 10 or more metabolites are simultaneously determined in said sample.
12. A computer-controlled medical diagnosis system for determining whether an individual suffers from a disease of the lower respiratory tract such as COPD or AECOPD, comprising
a. a computer and a mass spectrometer, wherein the mass spectrometer comprises
i. an ionization chamber and an inlet fluidly connected to the ionization chamber for providing a sample to said ionization
chamber, and
ii. a mass analysis and detector device capable of detecting metabolites and a data line connecting the mass analysis and detector device to a computer for providing data to the computer
wherein the computer is configured for
i. receiving data provided by the mass analysis and detector device to the computer using the data line and,
ii. processing said data such as to simultaneously determine the presence, absence or relative concentration of at least two metabolites in said sample on the basis of the data provided to said computer;
iii. comparing the determined presence, absence or relative concentration of at least two metabolites in said sample to predetermined reference values for said at least two metabolites, characterized in that the at least two metabolites are chosen from the group of metabolites emanating from of an oxidative or carbonyl stress process such as ω-oxidation products of linear fatty acids, from the group of metabolites of amino acids, from the group of metabolites emanating from nitrosative stress such as nitrophenol derivatives or from combinations of the metabolites of said groups, wherein preferably the metabolites of amino acids are in particular metabolites of nonpolar amino acids such as glycine, alanine, phenylalanine, proline valine, isoleucine and leucine, metabolites of polar amino acids such as lysine, ornithine, glutamic acid, aspartic acid, serine or cysteine and/or wherein preferably the metabolites emanating from of an oxidative or carbonyl stress process are derivatives of fatty acids, saturated or unsaturated, such as medium-chain fatty acids, long-chain fatty acids or very long-chain fatty acids, which are preferably hydroxylated, carbonylated or carboxylated derivatives thereof and/or wherein preferably the group of ω-oxidation products of linear fatty acids comprises o- hydroxyalkanoic acids (CxH2x03), co-oxoalkanoic acids (CxH2x-203) or alkanedioic acids (CxH2x.204) and/or wherein preferably the group of metabolites emanating from nitrosative stress such as nitrophenol derivatives includes nitrohydroquinones, dinitrophenols, nitrocatechols and
alkylated derivatives thereof.
13. The computer-controlled medical diagnosis system of claim 12, wherein the ionization chamber is configured to produce ions using an electrospray, and in particular is configured to produce ions using secondary electrospray ionization (SESI), and/or wherein the mass spectrometer is preferably a time-of-flight mass spectrometer.
14. The computer-controlled medical diagnosis system of claim 12 or 13, wherein the inlet is fluidly connected to the ionization chamber for providing a sample to said ionization chamber on one side, and on the other side is connected to a mouthpiece.
15. The computer-controlled medical diagnosis system of any of claims 12 to 14, wherein the computer is configured for
i. receiving data provided by the mass analysis and detector device to the computer using the data line and,
ii. processing said data such as to simultaneously determine the presence, absence or relative concentration of at least 3, 4, 5, 6, 7, 8 , 9, 10 or more metabolites in said sample on the basis of the data provided to said computer;
iii. comparing the determined presence, absence or relative concentration of said at least 3, 4, 5, 6, 7, 8 , 9, 10 or more metabolites in said sample to predetermined reference values for said of at least 3, 4, 5, 6, 7, 8 , 9, 10 or more metabolites.
16. Use of a computer-controlled medical diagnosis system according to any of claims 12 to 15 for determining whether an individual suffers from a disease of the lower respiratory tract such as COPD or AECOPD.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16176975 | 2016-06-29 | ||
EP16176975.7 | 2016-06-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018002173A1 true WO2018002173A1 (en) | 2018-01-04 |
Family
ID=56403959
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2017/066053 WO2018002173A1 (en) | 2016-06-29 | 2017-06-28 | Method of detecting copd by mass spectrometry |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2018002173A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2020054722A1 (en) * | 2018-09-12 | 2021-09-09 | 株式会社島津製作所 | How to measure COPD index value |
CN119619529A (en) * | 2025-02-14 | 2025-03-14 | 四川大学华西医院 | Salivary metabolic marker combination for diagnosis of COPD and screening method thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010031788A1 (en) | 2008-09-17 | 2010-03-25 | Universiteit Maastricht | Method for the diagnosis of chronic obstructive pulmonary disease by detecting volatile organic compounds in exhaled air |
US20120021532A1 (en) * | 2008-09-25 | 2012-01-26 | Biosystems International Sas | Methods of Detecting and Treating Pulmonary Disease and Markers Thereof |
US9121844B1 (en) | 2008-09-09 | 2015-09-01 | Sociedad Europea de Analisis Diferencial de Movilidad | Method to analyze and classify persons and organisms based on odor patterns from released vapors |
-
2017
- 2017-06-28 WO PCT/EP2017/066053 patent/WO2018002173A1/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9121844B1 (en) | 2008-09-09 | 2015-09-01 | Sociedad Europea de Analisis Diferencial de Movilidad | Method to analyze and classify persons and organisms based on odor patterns from released vapors |
WO2010031788A1 (en) | 2008-09-17 | 2010-03-25 | Universiteit Maastricht | Method for the diagnosis of chronic obstructive pulmonary disease by detecting volatile organic compounds in exhaled air |
US20120021532A1 (en) * | 2008-09-25 | 2012-01-26 | Biosystems International Sas | Methods of Detecting and Treating Pulmonary Disease and Markers Thereof |
Non-Patent Citations (11)
Title |
---|
BALAZS ANTUS ET AL: "Oxidative Stress in COPD: Molecular Background and Clinical Monitoring", CURRENT MEDICINAL CHEMISTRY, vol. 22, 1 January 2015 (2015-01-01), pages 627 - 650, XP055316523 * |
BERTINI IVANO ET AL: "Phenotyping COPD by1H NMR metabolomics of exhaled breath condensate", METABOLOMICS, SPRINGER NEW YORK LLC, US, vol. 10, no. 2, 31 July 2013 (2013-07-31), pages 302 - 311, XP035936254, ISSN: 1573-3882, [retrieved on 20130731], DOI: 10.1007/S11306-013-0572-3 * |
DIEGO GARCÍA-GÓMEZ ET AL: "Secondary electrospray ionization coupled to high-resolution mass spectrometry reveals tryptophan pathway metabolites in exhaled human breath", CHEMICAL COMMUNICATIONS - CHEMCOM., vol. 52, no. 55, 1 January 2016 (2016-01-01), pages 8526 - 8528, XP055316817, ISSN: 1359-7345, DOI: 10.1039/C6CC03070J * |
KON SSC; CANAVAN JL; JONES SE ET AL.: "Minimum clinically important difference for the COPD Assessment Test: a prospective analysis", LANCET RESPIR MED., vol. 2, no. 3, 2014, pages 195 - 203 |
KUBÁN PETR ET AL: "Exhaled breath condensate: Determination of non-volatile compounds and their potential for clinical diagnosis and monitoring. A review", ANALYTICA CHIMICA ACTA, vol. 805, 2013, pages 1 - 18, XP028790331, ISSN: 0003-2670, DOI: 10.1016/J.ACA.2013.07.049 * |
M.T. GAUGG ET AL: "110 On-line breath analysis with secondary electrospray ionization discriminates between COPD patients with and without frequent exacerbations", CHEST, vol. 151, no. 5, 1 May 2017 (2017-05-01) - 9 June 2017 (2017-06-09), US, pages A5, XP055395029, ISSN: 0012-3692, DOI: 10.1016/j.chest.2017.04.006 * |
MARIO CAZZOLA ET AL: "Analysis of exhaled breath fingerprints and volatile organic compounds in COPD", COPD RESEARCH AND PRACTICE, BIOMED CENTRAL LTD, LONDON, UK, vol. 1, no. 1, 6 October 2015 (2015-10-06), pages 7, XP021229450, ISSN: 2054-9040, DOI: 10.1186/S40749-015-0010-1 * |
MARTINEZ FJ; RACZEK AE; SEIFER FD ET AL.: "Development and initial validation of a self-scored COPD Population Screener Questionnaire (COPD-PS", COPD, vol. 5, no. 2, 2008, pages 85 - 95 |
PABLO MARTINEZ-LOZANO SINUES ET AL: "Breath Analysis in Real Time by Mass Spectrometry in Chronic Obstructive Pulmonary Disease", RESPIRATION., vol. 87, no. 4, 1 January 2014 (2014-01-01), CH, pages 301 - 310, XP055316810, ISSN: 0025-7931, DOI: 10.1159/000357785 * |
STANLEY AJ; HASAN I; CROCKETT AJ; VAN SCHAYCK OCP; ZWAR NA: "Validation of the COPD Diagnostic Questionnaire in an Australian general practice cohort: a cross-sectional study", PRIM CARE RESPIR J., vol. 23, no. 1, 2014, pages 92 - 97 |
THORN J; TILLING B; LISSPERS K; JORGENSEN L; STENLING A; STRATELIS G: "Improved prediction of COPD in at-risk patients using lung function pre-screening in primary care: a real-life study and cost-effectiveness analysis", PRIM CARE RESPIR J., vol. 21, no. 2, 2012, pages 159 - 166 |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2020054722A1 (en) * | 2018-09-12 | 2021-09-09 | 株式会社島津製作所 | How to measure COPD index value |
TWI739155B (en) * | 2018-09-12 | 2021-09-11 | 日商島津製作所股份有限公司 | Copd index-value measurement method |
JP7589914B2 (en) | 2018-09-12 | 2024-11-26 | 株式会社島津製作所 | Method for measuring COPD index values |
CN119619529A (en) * | 2025-02-14 | 2025-03-14 | 四川大学华西医院 | Salivary metabolic marker combination for diagnosis of COPD and screening method thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Herbig et al. | On-line breath analysis with PTR-TOF | |
Schwoebel et al. | Phase-resolved real-time breath analysis during exercise by means of smart processing of PTR-MS data | |
Lawal et al. | Exhaled breath analysis: a review of ‘breath-taking’methods for off-line analysis | |
JP7411281B2 (en) | Diagnosis of tuberculosis and other diseases using exhalation-related applications | |
Bregy et al. | Real-time mass spectrometric identification of metabolites characteristic of chronic obstructive pulmonary disease in exhaled breath | |
Belluomo et al. | Selected ion flow tube mass spectrometry for targeted analysis of volatile organic compounds in human breath | |
Martinez-Lozano Sinues et al. | Breath analysis in real time by mass spectrometry in chronic obstructive pulmonary disease | |
Buszewski et al. | Human exhaled air analytics: biomarkers of diseases | |
Vautz et al. | Breath analysis—performance and potential of ion mobility spectrometry | |
Szulejko et al. | Evidence for cancer biomarkers in exhaled breath | |
Kataoka et al. | Noninvasive analysis of volatile biomarkers in human emanations for health and early disease diagnosis | |
Beauchamp et al. | Real-time breath gas analysis for pharmacokinetics: monitoring exhaled breath by on-line proton-transfer-reaction mass spectrometry after ingestion of eucalyptol-containing capsules | |
Beck et al. | Potential of mass spectrometry in developing clinical laboratory biomarkers of nonvolatiles in exhaled breath | |
Cristescu et al. | Screening for emphysema via exhaled volatile organic compounds | |
KR20110128296A (en) | Exhaled respiratory condensate biomarker measuring apparatus and method | |
Kleeblatt et al. | Detection of gaseous compounds by needle trap sampling and direct thermal-desorption photoionization mass spectrometry: concept and demonstrative application to breath gas analysis | |
Konieczna et al. | Bioanalysis of underivatized amino acids in non-invasive exhaled breath condensate samples using liquid chromatography coupled with tandem mass spectrometry | |
WO2010031788A1 (en) | Method for the diagnosis of chronic obstructive pulmonary disease by detecting volatile organic compounds in exhaled air | |
Berchtold et al. | A new strategy based on real-time secondary electrospray ionization and high-resolution mass spectrometry to discriminate endogenous and exogenous compounds in exhaled breath | |
CN108088712A (en) | A kind of expiratory air sampling apparatus and the method for sampling for the detection of direct mass spectrography | |
Beauchamp et al. | Odorant detection by on-line chemical ionization mass spectrometry | |
WO2018002173A1 (en) | Method of detecting copd by mass spectrometry | |
Acharige et al. | Breath-based diagnosis of fungal infections | |
Williams et al. | Crowd-based breath analysis: assessing behavior, activity, exposures, and emotional response of people in groups | |
Slingers et al. | Real‐time versus thermal desorption selected ion flow tube mass spectrometry for quantification of breath volatiles |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17736611 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 17736611 Country of ref document: EP Kind code of ref document: A1 |